Sudeep Pharma Ltd.record Q2 revenue ₹197 Cr (+21%), EBITDA margin 37.2%

Sudeep Pharma's Q2 FY27 call, held on 29 October 2026, reported record quarterly revenue of ₹196.7 crore, up 21% on the year and 24% on the quarter, and record EBITDA of ₹73.2 crore, up 32%, at a margin of 37.2% against 34.1%.

Profit after tax grew 11% to ₹51.8 crore as other income fell and the tax rate rose to 27%. Pharma Food Nutrition revenue rose 57% to ₹142 crore, while Specialty Ingredients fell 25% to ₹54 crore after the government's Fortified Rice program was paused. The 51,000-ton Nandesari greenfield plant received FDA approval, with commercial supply from the second half, and the Dahej battery-grade iron phosphate plant is on track for April 2027, with binding offtake contracts due in Q4. Management expects Specialty Ingredients to return to growth in Q3 and Q4, margins to be sustained rather than expanded, and net working capital of 170 to 180 days excluding battery inventory. Sea freight added about ₹8 crore of selling cost that was absorbed, and net debt was ₹72.5 crore.